Melatonina
Anno: 2012
-
Riferimento:J Appl Toxicol. 2012 Dec;32(12):952-8.Azione della melatonina:Study on disruption of circadian rhythmicity in humans (children if possible) under long-term exposure to weak ELF MF.Target:Extremely low-frequency (ELF) magnetic fields (MF)
-
Riferimento:J Pineal Res. 2012 Apr;52(3):322-31.Azione della melatonina:Melatonin sensitizes human hepatoma cells to ER tress-induced apoptosis by down-regulating COX-2 xpression, incresing the levels of CHOP and decreaing the Bcl-2/Bax ratio.Target:Endoplasmin reticulum, Cyclooxygenase-2, Pro-apoptotic transcription factor.
-
Riferimento:Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):337-44.Azione della melatonina:Systemic effects of darkness and excessive melatonin synthesis enables cancer protection treatment for people living in light-deficient environment.Target:Racial/ethnic disparities
-
Riferimento:Oncol Rep. 2012 Aug;28(2):418-28.Azione della melatonina:Circadian system alteration and melatonin reduction, for exposure to light-at-night during night shift work, is the most valid hypotheses on the relation of shift work and breast cancer.Target:Night shift work
-
Titolo: A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkersRiferimento:Cancer Causes Control. 2012 Apr;23(4):609-16.Azione della melatonina:Effects of melatonin supplementation (3 mg oral melatonin, daily for 4 months) in postmenopausal breast cancer survivors.Target:Estradiol-lowering effects of melatonin.
-
Riferimento:Dig Dis Sci. 2012 Oct 10.Azione della melatonina:Supplementation by exogenous melatonin (20 and 40 mg/kg body weight) significantly reduces MTX-induced small intestinal damage.Target:Methotrexate (MTX).
Anno: 2013
-
Riferimento:BMC Cell Biol. 2013 Jan 7;14:1.Azione della melatonina:Melatonin enhance DNA repair capacity by affecting several key genes involved in DNA damage responsive pathways.Target:DNA repair capacity
-
Riferimento:Breast Cancer Res Treat. 2013 Feb;137(3):677-87.Azione della melatonina:Melatonin or a melatonin receptor agonist may be useful biologic additions in the treatment of some forms of triple negative human breast carcinoma.Target:TNBC